Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
557.33
-31.07 (-5.28%)
Streaming Delayed Price
Updated: 3:02 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
2 Rising Biotechs That Could Become the Next Novo Nordisk
↗
January 29, 2024
Each of these companies has a big market in its sights.
Via
The Motley Fool
2 Stocks That Could Soar This Year: Are They Buys?
↗
January 22, 2024
They might perform well in 2024, but how will they do beyond that?
Via
The Motley Fool
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
↗
January 12, 2024
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.
Via
Benzinga
3 Stocks That Could Be Monster Winners in 2024
↗
December 30, 2023
Don't be surprised if these three stocks take off in the new year.
Via
The Motley Fool
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
December 08, 2023
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.
Via
Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
↗
November 13, 2023
Via
Benzinga
These 2 Stocks Could Be About to Soar: Are They Buys?
↗
December 07, 2023
One thing is for certain -- both of these companies are innovators.
Via
The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
↗
November 30, 2023
These stocks just might have investors seeing double over the next few years.
Via
The Motley Fool
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
↗
November 21, 2023
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...
Via
Benzinga
Topics
ETFs
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
↗
November 17, 2023
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.
Via
Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
↗
November 14, 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.
Via
InvestorPlace
2 Risky Stocks With Massive Potential
↗
October 17, 2023
Neither is doing well this year.
Via
The Motley Fool
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street
↗
September 20, 2023
This company is on the brink of a major breakthrough.
Via
The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
September 13, 2023
Via
Investor Brand Network
10 Health Care Stocks Whale Activity In Today's Session
↗
November 02, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
October 19, 2023
Via
Benzinga
Nike, Carnival And 3 Stocks To Watch Heading Into Friday
↗
September 29, 2023
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today?
↗
September 28, 2023
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28.
Via
Benzinga
Topics
Stocks
The Latest Analyst Ratings for Madrigal Pharmaceuticals
↗
September 11, 2023
Via
Benzinga
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
↗
September 27, 2023
It has a good shot at commercializing a drug to treat a common liver disease.
Via
The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
↗
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...
Via
Benzinga
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line
↗
September 13, 2023
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures.
Via
Investor's Business Daily
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
↗
September 11, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to...
Via
Benzinga
Topics
Stocks
The 3 Best Biotech Stocks to Buy Now: September 2023
↗
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.
Via
InvestorPlace
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of
↗
August 30, 2023
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months.
Via
InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
↗
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.
Via
InvestorPlace
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?
↗
August 23, 2023
NASH treatments are projected to be one of the most sought-after indications in the coming years.
Via
The Motley Fool
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It
↗
August 23, 2023
NASH is a surprisingly common ailment, and the first treatments are on the way.
Via
The Motley Fool
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
↗
August 02, 2023
Novo Nordisk received some good news in a recent physician survey.
Via
The Motley Fool
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market
↗
June 30, 2023
Madrigal is working on gaining FDA approval for what could be the first NASH treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
